Back to discover

Protein / target

Friend leukemia integration 1 transcription factor

Encoded byFLI1Q01543Homo sapiensSwiss-Prot
UniProt: Q01543Ensembl: ENSG00000151702HGNC: HGNC:3749NCBI Gene: 2313
Small-molecule tractable
Druggability
High-Quality Ligand
2
Research papers

Protein at a glance

Biological role

Sequence-specific double-stranded DNA binding

Strongest disease association

Rare hemorrhagic disorder due to a constitutional platelet anomaly

Via encoding gene FLI1 · Genetic evidence · score 0.88

Research activity

Emerging research

2 papers · latest 2023

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Sequence-specific transcriptional activator.

View complete UniProt function annotation

Sequence-specific transcriptional activator (PubMed:24100448, PubMed:26316623, PubMed:28255014). Recognizes the DNA sequence 5'-C[CA]GGAAGT-3'

Subcellular location

Nucleus
Domains and Gene Ontology detail (19)

Domains & features

PNT

Gene Ontology

  • Cchromatin
  • Cnuclear body
  • Cnucleoplasm
  • Cnucleus
  • Fchromatin binding
  • FDNA binding
  • FDNA-binding transcription activator activity, RNA polymerase II-specific
  • FDNA-binding transcription factor activity
  • FDNA-binding transcription factor activity, RNA polymerase II-specific
  • FRNA polymerase II cis-regulatory region sequence-specific DNA binding
  • Fsequence-specific double-stranded DNA binding
  • Ftranscription cis-regulatory region binding

452 aa · 51 kDa · 4 isoforms

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Transcriptional regulationUniProt · GO
View supporting evidence

Transcriptional regulation

  • ·Sequence-specific transcriptional activator (PubMed:24100448, PubMed:26316623, PubMed:28…
  • ·DNA-binding transcription activator activity, RNA polymerase II-specific
  • ·DNA-binding transcription factor activity
  • ·DNA-binding transcription factor activity, RNA polymerase II-specific

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene FLI1

Gene-level evidence surfaced through the gene FLI1that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Rare hemorrhagic disorder due to a constitutional platelet anomaly
0.88Well supported

Genetic evidence dominant · Open Targets 0.76

Sarcoma, Ewing
0.61Moderately supported

Genetic literature evidence dominant · Open Targets 0.42

Osteosarcoma
0.46Limited support

Somatic mutation evidence dominant · Open Targets 0.39

Rhabdomyosarcoma
0.41Limited support

Somatic mutation evidence dominant · Open Targets 0.37

View evidence synthesis (4)
Rare hemorrhagic disorder due to a constitutional platelet anomalyWell supported
0.88
agreement 0.76–1.00
Genetic100%Genetic literaturedup

Open Targets aggregate 0.76 · 1 independent evidence family · 1 not counted as duplicate

Sarcoma, EwingModerately supported
0.61
agreement 0.48–0.73
Genetic literature66%Literature20%Pathway14%

Open Targets aggregate 0.42 · 3 independent evidence families

OsteosarcomaLimited support
0.46
agreement 0.30–0.62
Somatic mutation79%Literature22%

Open Targets aggregate 0.39 · 2 independent evidence families

RhabdomyosarcomaLimited support
0.41
agreement 0.24–0.57
Somatic mutation96%Literature5%

Open Targets aggregate 0.37 · 2 independent evidence families

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Rare hemorrhagic disorder due to a constitutional platelet anomaly0.76
Sarcoma, Ewing0.42
Osteosarcoma0.39
Rhabdomyosarcoma0.37

Tractability

Small molecules — Emerging

Feasibility evidence (high-quality ligand) — no clinical-stage drug of this modality recorded.

Protein degraders — Emerging

Feasibility evidence (database ubiquitination and half-life data) — no clinical-stage drug of this modality recorded.

View underlying tractability evidence (4)
SM · High-Quality LigandPR · Database UbiquitinationPR · Half-life DataPR · Small Molecule Binder

Raw Open Targets tractability assessment buckets, by modality.

Research activity

2 papers · to 2023

Papers linked directly to this protein. This is the protein's own literature — descriptor-derived papers are kept separate below.

Most cited

Ewing's Sarcoma.274 cites

Riggi N · The New England journal of medicine · 2021

Cancer-Associated Fibroblast-Like Tumor Cells Remodel the Ewing Sarcoma Tumor Microenvironment.31 cites

Wrenn ED · Clinical cancer research : an official journal of the American Association for Cancer Research · 2023

Recent

Cancer-Associated Fibroblast-Like Tumor Cells Remodel the Ewing Sarcoma Tumor Microenvironment.

Wrenn ED · Clinical cancer research : an official journal of the American Association for Cancer Research · 2023

Ewing's Sarcoma.

Riggi N · The New England journal of medicine · 2021

Europe PMC papers linked directly to this protein.